THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION WILL BE CONSIDERED TO BE IN THE PUBLIC DOMAIN.

11 March 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Strengthens Board with Appointment of Pharmaceutical Industry Executive Dr. Renata Crome as Non-Executive Director

Solvonis Therapeutics plc (LSE:SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, is pleased to announce the appointment of pharmaceutical industry veteran, Dr. Renata Crome DSc, MBA, MFPM, as an independent Non-Executive Director, effective from 11 March 2025.

Dr. Crome brings over 40 years of experience in scientific and clinical development, regulatory approval, and commercialisation of breakthrough medicines. A recognised leader in CNS (Central Nervous System), oncology, and infectious diseases, Dr. Crome has guided more than 100 novel therapies from early-stage research to first-in-human clinical trials.

During her 30-year tenure at Roche, Dr. Crome progressed through increasingly senior roles, ultimately becoming Deputy Head of Early Development & Global Head of Development Operations. In this capacity, she led a team of over 250 professionals and managed a portfolio of more than 100 early development programmes across several therapeutic areas, including CNS, a key area of focus for Solvonis.

Dr. Crome's strategic leadership has been pivotal in the commercialisation of several blockbuster drugs, including leading the prioritisation of Avastin® and Tamiflu®, resulting in rapid regulatory approvals and the realisation of US$7 billion and US$3 billion peak annual sales respectively for Roche. These achievements reflect her ability to drive the development of impactful treatments, especially in therapeutic areas closely aligned with Solvonis's commitment to addressing mental health and addiction.

Currently, Dr. Crome consults for Novo Nordisk, advising on early-stage drug development strategies, and previously led the UK Government's UKRI-sponsored COVID-19 treatments programme.

Dr. Crome also served as a Non-Executive Director at Camcon Robotics and is a Trustee for the PTEN Research Foundation, Success Charity and Isabel Hospice. Her involvement in academia includes lecturing at the University of Hertfordshire and chairing the Infectious Diseases Expert Group within the Faculty of Pharmaceutical Medicine's Policy & Communications Group.

Dennis Purcell, Chair of Solvonis Therapeutics plc, commented: "We are thrilled to welcome Dr. Renata Crome to the Board. Her extensive experience in drug development, regulatory affairs, and commercial strategy, combined with her governance expertise, will be invaluable as Solvonis continues to advance its innovative therapies in the mental health and addiction spaces."

Dr. Crome added: "I am excited to join Solvonis at such a transformative time. The Company's dedication to addressing unmet needs in addiction and mental health through pioneering science is inspiring. I look forward to collaborating with the Board and leadership team to help drive the development of groundbreaking therapies."

Pursuant to Listing Rule 9.6.13, there are no other details to disclose regarding this appointment.

Enquiries:

Solvonis Therapeutics plc, Anthony Tennyson, CEO & Executive Director, Email: anthony@solvonis.com

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance) | Guy McDougall (Sales)

About Solvonis Therapeutics plc

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders. Solvonis' mission is to improve outcomes for individuals suffering from mental health disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.

www.solvonis.com | LinkedIn | X (formerly Twitter)